I-SPY2 PUBLICATIONS & ABSTRACTS

Clinical evidence from I-SPY2


Evidence / Neoadjuvant / I-SPY2

BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2

AACR, Poster 2612 AUTHORS: Pei Rong Evelyn Lee, Zelos Zhu, Denise Wolf, Christina Yau, William Audeh, Annuska Glas, Lamorna Brown-Swigart, Gillian Hirst, Angela DeMichele, ISPY2 TRIAL Investigators, Laura Esserman and Laura van โ€˜t Veer DESCRIPTION: BluePrint Luminal subtype predicts non-response to HER2-targeted therapies in HR+/HER2+ I-SPY2 breast cancer patients BluePrintยฎ Read More

DNA Repair Deficiency Biomarkers and the 70-Gene Ultra-High Risk Signature as Predictors of Veliparib/Carboplatin Response in the I-SPY 2 Breast Cancer Trial

PUBLICATION: NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. AUTHORS: Wolf D.M., Yau C., Sanil A., Glas A., Petricoin E., Wulfkuhle J., Severson T.M., Linn S., Brown-Swigart L., Hirst G., Buxton M., DeMichele A., Hylton N., Symmans F., Yee D., Paoloni M., Esserman L., Berry D., Rugo H., Olopade O., Read More